KAL 1.0
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Callisto Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of drugs to treat multiple myeloma, other cancers, and osteolytic bone diseases. Its lead drug candidate, Atiprimod, which completed single and multiple dose Phase I clinical trials, is a small-molecule, orally available drug with antiproliferative and antiangiogenic activity. The company intends to initiate Phase IIb clinical trials of Annamycin, a drug to treat leukemia, including activity against resistant diseases and reduced toxicity. It also has drugs in preclinical development for melanoma, gastrointestinal inflammation, and a program focused on the development of a drug to protect against staphylococcus and streptococcus biowarfare agents. |
